Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology; Non-interventional, Observational, Prospective Study

NCT01626547 is registered in ClinicalTrials.gov with Hospira, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT01626547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01626547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology; Non-interventional, Observational, Prospective Study
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Phase
Observational
Overall status
Completed
Start date
December 31, 2010
Completion date
July 31, 2013
Enrollment
291 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced symptomatic anaemia, malignant lymphomas, multiple myeloma, solid tumours